Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics ...Middle East

HONG KONG and GERMANTOWN, Md. and SUZHOU, China, July 8, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or "Sirnaomics"; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi...

Hence then, the article about sirnaomics announces interim results for successful completion of the second cohort of phase i clinical study of galnac based rnai therapeutic stp122g for anticoagulant therapeutics was published today ( Monday 08/07/2024 - 09:29 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics )

Also on site :

• This Landmark Was Just Ranked ‘Most Loved in the World’—and It's Not the Eiffel Tower
• This Savory New $5 Sam’s Club Snack Puts the Dip in the Chip
• Mindy Kaling Says Her Recent Weight Loss Has Nothing to Do With the Red Carpet